Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.

@article{Puhr2012EpithelialtomesenchymalTL,
  title={Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.},
  author={Martin Puhr and Julia Hoefer and Georg Sch{\"a}fer and Holger H. H. Erb and Su Jung Oh and Helmut Klocker and Isabel Heidegger and Hannes Neuwirt and Zoran Culig},
  journal={The American journal of pathology},
  year={2012},
  volume={181 6},
  pages={2188-201}
}
Docetaxel is a standard chemotherapy for patients with metastatic prostate cancer. However, the response is rather limited and not all of the patients benefit from this treatment. To uncover key mechanisms of docetaxel insensitivity in prostate cancer, we have established docetaxel-resistant sublines. In this study, we report that docetaxel-resistant cells underwent an epithelial-to-mesenchymal transition during the selection process, leading to diminished E-cadherin levels and up-regulation of… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 99 extracted citations

Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel

Journal of experimental & clinical cancer research : CR • 2017
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…